|Bid||1.0000 x 4000|
|Ask||1.0500 x 3000|
|Day's Range||1.0000 - 1.0500|
|52 Week Range||1.0000 - 3.2000|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 1, 2018 - Aug 6, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||2.00|
ReWalk Robotics CEO Larry Jasinski and Restore Exo-Suit Product Manager Kathleen O'Donnell on a new exoskeleton developed to help stroke survivors walk.
ReWalk Robotics, Ltd. (RWLK) (“ReWalk” or “the Company”) announced today that the Company’s ReWalk Personal 6.0 Exoskeleton System has been included in the official list of medical aids (Hilfsmittelverzeichnis) by the German National Association of Statutory Health Insurance Funds (GKV-Spitzenverband). ReWalk Personal 6.0 Exoskeleton System is the first and only exoskeleton device for individuals with spinal cord injury included in the national list (according to §139 SGB V), which makes the device officially recognized as a medical aid (according to §33 SGB V) throughout Germany. The addition of ReWalk Personal 6.0 Exoskeleton System to the list, which is drawn up and regularly updated by the GKV-Spitzenverband, was announced this week in the Federal Gazette through the German Ministry of Justice and Consumer Protection.
ReWalk Robotics Ltd. (RWLK) (“ReWalk” or “the Company”) announced today that the Company has received the first tranche of $5 million in funding as part of the $20 million strategic investment by Timwell Corporation Limited (“Timwell”), a Hong Kong corporation, and has appointed Ning Cong to its Board of Directors. The strategic investment transaction was originally announced on March 8, 2018.
The Yokneam Ilit, Israel-based company said it had a loss of 21 cents per share. Losses, adjusted for non-recurring costs, were 18 cents per share. The maker of wearable robotic exoskeletons that help ...
ReWalk shareholders approve $20 million investment agreement with Timwell Corporation Limited Total revenue of $1.6 million during the first quarter of 2018 YOKNEAM ILIT, ISRAEL and MARLBOROUGH, Mass., ...
MARLBOROUGH, Mass. and YOKNEAM ILIT, Israel, May 09, 2018-- ReWalk Robotics Ltd., a leading manufacturer of exoskeleton systems, will release its first quarter 2018 financial results on Thursday, May 10, ...
ReWalk Robotics, Ltd. (RWLK) (“ReWalk” or “the Company”) announced today that the Company has appointed Yohanan Engelhardt to the Board of Directors and as Chairman of its Audit Committee. Mr. Engelhardt is a seasoned financial executive who has spent the last 25 years helping companies realize enterprise-wide improvements in financial reporting, financial and operational controls and expenses, capital funding, and taxation. Mr. Engelhardt provides CFO-consulting accounting services to early-stage technology and medical device companies.
MARLBOROUGH, Mass. and YOKNEAM ILIT, Israel, April 3, 2018 /PRNewswire/ -- ReWalk Robotics Ltd. (RWLK) ("ReWalk" or the "Company"), a leading manufacturer of robotic exoskeletons, announced today the official launch of its clinical study of the ReStore soft exo-suit system (ReStore) for the rehabilitation of individuals with lower limb disability due to stroke. The first clinical study participant began using a ReStore last week at the Spaulding Rehabilitation Hospital in Boston, Massachusetts where the study is being led by a team of researchers from the Boston University College of Health and Rehabilitation Sciences: Sargent College.
MARLBOROUGH, Mass. and YOKNEAM ILIT, Israel, March 21, 2018 /PRNewswire/ -- ReWalk Robotics Ltd. (RWLK) ("ReWalk" or "the Company"), a leading manufacturer of robotic exoskeletons, today announced that INAIL, the Italian Ministry of Labor and Social Policy's statutory insurance corporation, has put in place a coverage policy that will provide exoskeleton systems for all qualifying beneficiaries. This policy, the first of its kind in Italy, will provide individuals with spinal cord injury access to obtain their own medical device so that they can stand and walk again. "The INAIL policy is a milestone in the adoption of exoskeleton technology for the people of Italy, and will serve as a precedent in helping many more injured workers around the world gain access to this impactful medical device," said ReWalk CEO Larry Jasinski.
Stock Monitor: K2M Group Holdings Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 12, 2018 / Active-Investors.com has just released a free research report on ReWalk Robotics Ltd (NASDAQ: RWLK ) ...
On a per-share basis, the Yokneam Ilit, Israel-based company said it had a loss of 25 cents. The maker of wearable robotic exoskeletons that help paralyzed patients walk posted revenue of $1.5 million ...
ReWalk Robotics Ltd (NASDAQ:RWLK), a medical equipment company based in Israel, saw its share price hover around a small range of $1.05 to $1.15 over the last few weeks. ButRead More...
MARLBOROUGH, Mass. and BERLIN, Feb. 1, 2018 /PRNewswire/ -- GKV-Spitzenverband, the head office of German statutory health insurance (SHI), confirmed their decision to list the ReWalk (RWLK) Personal 6.0 Exoskeleton System in the German Medical Device Directory (MDD, Hilfsmittelverzeichnis), according to §139 SGB V. The MDD is a comprehensive list of all medical devices which are principally and regularly reimbursed by German SHI providers. This decision means that ReWalk will be listed among all medical devices for compensation, which SHI providers can procure for any approved beneficiary on a case-by-case basis.
While small-cap stocks, such as ReWalk Robotics Ltd (NASDAQ:RWLK) with its market cap of $32.95M, are popular for their explosive growth, investors should also be aware of their balance sheetRead More...
When ReWalk Robotics Ltd (NASDAQ:RWLK) released its most recent earnings update (30 September 2017), I wanted to understand how these figures stacked up against its past performance. The two benchmarksRead More...
MARLBOROUGH, Mass. and YOKNEAM ILIT, Israel, Nov. 30, 2017 /PRNewswire/ -- ReWalk Robotics' (RWLK) ("ReWalk" or the "Company") innovative Restore soft exoskeleton system was featured in a recent story as one of the cutting edge technologies seeking to help stroke survivors heal and retain critical motor skills. The story published in Medical Device & Diagnostic Industry (MD&DI), a leading industry trade magazine. Priced at $19,500, the soft exosuit is anticipated to begin commercialization in late 2018 or early 2019.
While many momentum-focused investors focus on buying stocks near new highs and hoping the upward trend continues, other investors find value in searching for stocks that are poised to rebound after hitting new lows. Check out these slumping stocks that could be poised for a rebound soon.